The ESMO Colloquia are innovative sessions within the congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.
View the complete ELCC 2022 Congress programme
One Tumour, Many Faces: Optimising Testing, Targeting and Monitoring Oncogene-Addicted NSCLC beyond EGFR
Thursday, 31 March 2022, 11:45 - 13:15 CEST (Central European Summer Time)
View the ESMO Colloquium details
This educational activity is provided by ESMO and co-supported by Eli Lilly
- To provide an update on molecular epidemiology, testing technologies and the role of molecular tumour boards for patients with advanced non-small cell lung cancer harbouring non-EGFR, rare molecular aberrations.
- To provide an overview of therapeutic pathways available in non-EGFR oncogene-driven advanced non-small cell lung cancer.
- To highlight state of the art management strategies for patients with RET-driven NSCLC, including disease control in sanctuary sites